March 6, 2020

Alston & Bird Healthcare Week in Review, March 6, 2020

Below is Alston & Bird’s Healthcare Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.


Week in Review Highlight of the Week:

Congress approved an $8.3 billion supplemental funding package to respond to the COVD-19 outbreak. Read more about this week’s congressional and regulatory activity below.


I. Regulations, Notices, & Guidance

Event Notices

  • March 9, 2020: FDA and the Federal Trade Commission (FTC) announced a public workshop entitled, Workshop on a Competitive Marketplace for Biosimilars. The purpose of the public workshop is to discuss FDA and FTC's collaborative efforts to support appropriate adoption of biosimilars, discourage false or misleading communications about biosimilars, and deter anticompetitive behaviors in the biologic product marketplace.
  • March 10, 2020: FDA announced a public meeting entitled, Patient-Focused Drug Development for Stimulant Use Disorder. The purpose of the meeting is to allow FDA to obtain stakeholder perspectives on the impact of stimulant use disorder and views on treatment approaches for stimulant use disorder.
  • April 15, 2020: the National Institutes of Health (NIH) announced a Committee meeting of the National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID Resource-Related Research Projects.

II. Congressional Hearings

U.S. Senate

House of Representatives

III. Reports, Studies, & Analyses

  • On March 4, 2020, the Congressional Budget Office (CBO) issued a cost estimate on H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. The bill would authorize $7.7 billion in discretionary funding to respond to the outbreak and $490 million for changes to telemedicine payment requirements under Medicare to treat seniors remotely.

IV. Other Health Policy News

  • On March 5-6, 2020, the Medicare Payment and Access Commission held their March meeting. The meeting agenda is accessible here.
  • On March 5, 2020, the Centers for Medicare & Medicaid Services (CMS) developed a Healthcare Common Procedure Coding System (HCPCS) code that laboratories can use to bill for COVID-19 diagnostic tests. Last month, CMS developed a code that was specific to Centers for Disease Control and Prevention (CDC) labs to test for SARSCoV-2. This new code allows laboratories to bill for non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19). Additional information regarding the new code is available here.

Click here to view the members of our Health Care Legislative & Public Policy team.

Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.